Hypertension Management in Cancer Patients

NATerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

December 10, 2019

Primary Completion Date

June 3, 2020

Study Completion Date

June 3, 2020

Conditions
Blood PressureHypertensionCancerCancer, BreastCancer of ProstateCLLHematopoietic Malignancy
Interventions
OTHER

Automated Messaging

This is a 12-week prospective study with two phases. Participants will use the QardioArm device to obtain 3 separate blood pressure measurements per week (2 morning, 1 evening). The QardioArm device will only be used as a tool to gather data. In Phase 1 (Weeks 1-4), participants will self-monitor their blood pressure using the Qardio Bluetooth device. In Phase 2 (Weeks 5-12), we will implement the auto-messaging system triggered by a weekly average systolic blood pressure \>140 mm Hg or diastolic blood pressure \>90 mm Hg.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

Duke Institute for Health Innovation

UNKNOWN

lead

Duke University

OTHER

NCT03919214 - Hypertension Management in Cancer Patients | Biotech Hunter | Biotech Hunter